Nithin Mummaneni is the founder and CEO of Infinity Loop.
A 300-page pharmaceutical outsourcing agreement can clear legal, quality, regulatory and technical review without anyone asking whether the price is competitive.
Each department reviews the agreement through its own responsibilities. Legal looks at liability, quality reviews manufacturing obligations, and regulatory and technical teams cover their respective areas. What can get lost is the commercial picture: the rates, annual increases, payment arrangements and scope that determine what the business will actually pay.
I spent years as a management consultant running contract negotiations for Fortune 500 companies and private equity portfolios. In pharmaceuticals, I rarely met a team that had benchmarked its payment terms or escalation provisions against comparable agreements. We could provide that analysis, but the cost of the analysis could outweigh potential savings, making it difficult for companies to justify. As a result, procurement teams remain in the dark about whether an agreement is commercially competitive. A contract can be fully approved without anyone knowing whether the company is overpaying or leaving savings on the table.
Separate Documents, Connected Costs
The most expensive parts of a pharmaceuticals contract are usually the change-control clauses.
The FDA recommends keeping quality agreements separate from the commercial contract, or structured so they can be separated. This keeps manufacturing responsibilities from getting tangled up with pricing, delivery and liability limits. That makes sense for compliance. It also means a quality team can approve a document that affects costs without anyone in the room reviewing the pricing implications.
Before signing, procurement should understand which required activities are included in the quoted price, what triggers additional charges and how a change affects delivery dates and payments. Quality requirements and change-control obligations both affect what ends up on the invoice, whether or not the teams reviewing them consider that cost.
Switching constraints give suppliers pricing power.
Timing matters, too. When scientists or operations teams select the supplier and set the scope first, procurement often joins after the decisions that shape the deal have already been made. By the time the contract reaches procurement, the team is left trying to improve pricing on a deal it had little opportunity to influence.
This often happens with incumbent suppliers. There is value in staying with a provider that has already been qualified, and few pharmaceutical companies want to take on continuity risk unless they have to. Suppliers understand that and often price accordingly.
A proven contract development and manufacturing organization (CDMO) can earn a premium. Procurement’s job is to understand how much of that premium reflects the provider’s capability and how much reflects the difficulty of switching.
Even when switching is off the table, there is still room to negotiate payment arrangements, annual increases, scope and change orders. Understanding those constraints helps procurement decide what to ask for and how to approach the conversation.
More Relationships, More Agreements
Organizations keep outsourcing more. The average organization now works with 286 third-party vendors, up 21% year over year, according to Whistic’s 2025 third-party risk management report.
Lonza’s 2025 annual report describes continued outsourcing in biologics as demand grows and more molecules move toward commercialization. Each new relationship adds contracts, amendments and a performance history that someone needs to understand before the next renewal. Those records often sit across different functions and systems.
Procurement managers preparing for a renewal may have the signed contract and little else. To understand what the supplier actually delivered or what has changed in the new proposal, they have to request information from other teams and compare documents manually.
That work is slow and expensive. If the evidence only comes together after the renewal has been signed, it is too late to use it to shape that negotiation.
Bring the evidence before the signature.
At one global biopharmaceutical company, my company analyzed $350.3 million in spend across its network of outsourced research and development providers. We identified $24.6 million in actionable savings, about 7% of spend. We found those opportunities by bringing contract, supplier and market data together, giving procurement a clearer picture of where it had leverage, what to ask for and how to approach the negotiation.
Paying more for a proven partner may make sense. But the team should understand the rates it is paying and how they compare to the market before making that decision. It should be a deliberate choice.
Before the next agreement is signed, settle three things: who owns the price review, when it happens and what evidence it needs. Then bring procurement in early enough to act on what it finds. The review matters most when there’s still time to change the deal.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

